Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
34.01
-0.90 (-2.59%)
Aug 17, 2026, 12:01 PM EDT - Market open
Tectonic Therapeutic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
60
Market Cap
664.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 174.48M |
| Valneva SE | 163.30M |
| Zevra Therapeutics | 136.07M |
| Gyre Therapeutics | 109.82M |
| 4D Molecular Therapeutics | 92.01M |
| Assembly Biosciences | 74.85M |
| Allogene Therapeutics | 4.64M |
| Neurogene | 925.00K |
TECX News
- 10 days ago - Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 11 days ago - Tectonic Therapeutic Quarterly report: Q2 2026 - Filings
- 11 days ago - Tectonic Therapeutic Earnings release: Q2 2026 - Filings
- 16 days ago - Tectonic Therapeutic Slides: Investor presentation - Filings
- 2 months ago - Tectonic Therapeutic completes enrollment for APEX trial - TheFly
- 2 months ago - Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients - GlobeNewsWire
- 2 months ago - Tectonic Therapeutic Transcript: AGM 2026 - Transcripts
- 2 months ago - Tectonic Therapeutic upgraded to Strong Buy from Outperform at Raymond James - TheFly